Clinical research of IA regimen as induction chemotherapy for acute myeloid leukemia

Abstract

Objective To explore the clinical efficacy and toxicity of idarubicin (IDA)-based IA regimen as induction chemotherapy in treating acute myeloid leukemia (AML) within different risk groups.Methods Data collected in 60 patients initially diagnosed and treated with one course of IA regimen were studied retrospectively.Results Efficacy were different for patients treatment with different prognosis after one course of IA chemotherapy,CR rates achieved in patients with favorable,intermediate and unfavorable prognosis were 83.3 ％ (10/12),73.1％ (19/26),59.1％ (13/22) respectively,PR rates were 16.7 ％ (2/12),19.2％ (5/26),13.6％ (3/22) while ORrateswere 100％ (12/12),92.3 ％ (24/26),72.7 ％ (15/22)respectively.After 2 years of follow-up,relapse free survival (RFS) rates were 100 ％ for patients with good prognosis,53.8 ％ for those with moderate prognosis,and 45.5 ％ for people with poor prognosis.The outcome showed that there were significant differences among these three group (P =0.042).Myelosuppression and infections due to neutropenia were the main adverse effects,and severe non-hematologic toxicities were not observed.Conclusion IA regimen as induction chemotherapy may be an efficacious and safe solution and achieve a higher CR rate and 2 years RFS rate for patients diagnosed as AML with good prognosis.Hematopoietic stem cell transplantation should be considered as soon as possible for patients with moderate or poor prognosis. Key words: Leukemia, myeloid, acute; Drug therapy, combination